UPDATE 2-Teva wins US patent case on birth control pill
* Upholds Seasonique patent in case vs Watson
* Still has pending Seasonique cases in NJ (Adds sales data, Watson comment)
NEW YORK, April 1 (Reuters) - A U.S. federal court has upheld a patent for Teva Pharmaceutical Industries Ltd's (TEVA.TA) Seasonique birth-control pill in a case against generic drugmaker Watson Pharmaceuticals Inc WPI.N, Teva said on Thursday.
The U.S. District Court for the District of Nevada granted Teva's motion for summary judgment, rendering a trial unnecessary, Israel-based Teva TEVA.O said.
Watson had sought to sell a U.S. generic version of Seasonique before the patent expires in January 2024. Seasonique had $82.6 million in U.S. sales last year, Teva said, citing data from market research firm IMS Health.
Teva is the world's largest generic drugmaker, but it also sells a clutch of brand name drugs such as Seasonique, primarily in specialty markets.
A Watson spokesman said the company was disappointed in the ruling and intends to appeal it.
Teva is involved in separate litigation in the U.S. District Court for the District of New Jersey involving applications for generic versions of Seasonique from Mylan Inc (MYL.O) and Lupin Ltd (LUPN.BO).
Teva said it is analyzing the impact of the Nevada decision on those cases.
Teva shares were up 1.0 percent at $63.69 on Nasdaq. Watson shares rose 1.4 percent to $42.35 on the New York Stock Exchange. (Reporting by Lewis Krauskopf, editing by Dave Zimmerman, editing by Gerald E. McCormick)
- Anger mounts after bodies found trapped inside sunken South Korean ferry |
- Vice-principal of South Korea school in ferry disaster commits suicide |
- Special Report: How the U.S. made its Putin problem worse
- Search resumes after Everest's worst climbing tragedy
- All 338 Korean students, teachers rescued from sinking ferry - school official